Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

288 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
1-Sulfonyl-6-Piperazinyl-7-Azaindoles as potent and pseudo-selective 5-HT6 receptor antagonists.
Fabritius CH, Pesonen U, Messinger J, Horvath R, Salo H, Gałęzowski M, Galek M, Stefańska K, Szeremeta-Spisak J, Olszak-Płachta M, Buda A, Adamczyk J, Król M, Prusis P, Sieprawska-Lupa M, Mikulski M, Kuokkanen K, Chapman H, Obuchowicz R, Korjamo T, Jalava N, Nowak M. Fabritius CH, et al. Among authors: messinger j. Bioorg Med Chem Lett. 2016 Jun 1;26(11):2610-5. doi: 10.1016/j.bmcl.2016.04.024. Epub 2016 Apr 23. Bioorg Med Chem Lett. 2016. PMID: 27117428
Substituted 6-phenyl-2-naphthols. Potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1): design, synthesis, biological evaluation, and pharmacokinetics.
Marchais-Oberwinkler S, Kruchten P, Frotscher M, Ziegler E, Neugebauer A, Bhoga U, Bey E, Müller-Vieira U, Messinger J, Thole H, Hartmann RW. Marchais-Oberwinkler S, et al. Among authors: messinger j. J Med Chem. 2008 Aug 14;51(15):4685-98. doi: 10.1021/jm800367k. Epub 2008 Jul 17. J Med Chem. 2008. PMID: 18630892
Design, synthesis, and biological evaluation of (hydroxyphenyl)naphthalene and -quinoline derivatives: potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) for the treatment of estrogen-dependent diseases.
Frotscher M, Ziegler E, Marchais-Oberwinkler S, Kruchten P, Neugebauer A, Fetzer L, Scherer C, Müller-Vieira U, Messinger J, Thole H, Hartmann RW. Frotscher M, et al. Among authors: messinger j. J Med Chem. 2008 Apr 10;51(7):2158-69. doi: 10.1021/jm701447v. Epub 2008 Mar 7. J Med Chem. 2008. PMID: 18324762
Structure-activity study in the class of 6-(3'-hydroxyphenyl)naphthalenes leading to an optimization of a pharmacophore model for 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) inhibitors.
Marchais-Oberwinkler S, Frotscher M, Ziegler E, Werth R, Kruchten P, Messinger J, Thole H, Hartmann RW. Marchais-Oberwinkler S, et al. Among authors: messinger j. Mol Cell Endocrinol. 2009 Mar 25;301(1-2):205-11. doi: 10.1016/j.mce.2008.09.024. Epub 2008 Oct 4. Mol Cell Endocrinol. 2009. PMID: 18950679
New inhibitors of 17beta-hydroxysteroid dehydrogenase type 1.
Messinger J, Hirvelä L, Husen B, Kangas L, Koskimies P, Pentikäinen O, Saarenketo P, Thole H. Messinger J, et al. Mol Cell Endocrinol. 2006 Mar 27;248(1-2):192-8. doi: 10.1016/j.mce.2005.11.044. Epub 2006 Jan 18. Mol Cell Endocrinol. 2006. PMID: 16413669
288 results